<code id='FBE5034670'></code><style id='FBE5034670'></style>
    • <acronym id='FBE5034670'></acronym>
      <center id='FBE5034670'><center id='FBE5034670'><tfoot id='FBE5034670'></tfoot></center><abbr id='FBE5034670'><dir id='FBE5034670'><tfoot id='FBE5034670'></tfoot><noframes id='FBE5034670'>

    • <optgroup id='FBE5034670'><strike id='FBE5034670'><sup id='FBE5034670'></sup></strike><code id='FBE5034670'></code></optgroup>
        1. <b id='FBE5034670'><label id='FBE5034670'><select id='FBE5034670'><dt id='FBE5034670'><span id='FBE5034670'></span></dt></select></label></b><u id='FBE5034670'></u>
          <i id='FBE5034670'><strike id='FBE5034670'><tt id='FBE5034670'><pre id='FBE5034670'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:61

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In